Yuxian Bai
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis 26
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies 59
- Cancer Immunotherapy and Biomarkers 38
- Pancreatic and Hepatic Oncology Research 23
- Gastroenterology top 1%
- Gastrointestinal Tumor Research and Treatment 18
- Pulmonary and Respiratory Medicine top 0.5%
- Gastric Cancer Management and Outcomes 63
- Lung Cancer Treatments and Mutations 27
- Cancer Research top 2%
-
- Esophageal Cancer Research and Treatment 28
- Co-authors
- Shukui QinJianming XuYing ChengTianshu LiuYanjing LiJianping XiongZhenggang RenHongming Pan
- Cited by
- HepatologyOncologyGastroenterology
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Yuxian Bai
177 papers receiving 5.9k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Hepatology 1.4k
- Oncology 3.2k
- Gastroenterology 426
- Pulmonary and Respiratory Medicine 2.3k
- Cancer Research 1.0k
Countries citing papers authored by Yuxian Bai
This map shows the geographic impact of Yuxian Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuxian Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuxian Bai more than expected).
Fields of papers citing papers by Yuxian Bai
This network shows the impact of papers produced by Yuxian Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuxian Bai. The network helps show where Yuxian Bai may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yuxian Bai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 5 | |
| 4 | 2024 | 16 | |
| 5 | 2024 | 5 | |
| 6 | 2024 | 4 | |
| 7 | 2023 | 3 | |
| 8 | 2023 | 3 | |
| 9 | 2023 | 0 | |
| 10 | 2022 | 75 | |
| 11 | Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trialbreakdown → | 2022 | 127 |
| 12 | 2022 | 7 | |
| 13 | The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerbreakdown → | 2021 | 449 |
| 14 | 2020 | 70 | |
| 15 | 2020 | 13 | |
| 16 | 2019 | 38 | |
| 17 | 2019 | 23 | |
| 18 | 2019 | 23 | |
| 19 | 2017 | 63 | |
| 20 | 22. Expression and clinical significance of TF and Her-2 in gastric carcinoma | 2012 | 1 |
About Yuxian Bai
Yuxian Bai is a scholar working on Oncology, Gastroenterology and Hepatology, having authored 187 papers that have together received 6.0k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (63 papers), Colorectal Cancer Treatments and Studies (59 papers), Cancer Immunotherapy and Biomarkers (38 papers), Esophageal Cancer Research and Treatment (28 papers), Lung Cancer Treatments and Mutations (27 papers), Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Pancreatic and Hepatic Oncology Research (23 papers) and Gastrointestinal Tumor Research and Treatment (18 papers). The work is most often cited by research in Hepatology (1.4k citations), Oncology (3.2k citations) and Gastroenterology (426 citations). Yuxian Bai has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Shukui Qin, Jianming Xu, Ying Cheng, Tianshu Liu, Yanjing Li, Jianping Xiong, Zhenggang Ren, Hongming Pan, Rui‐Hua Xu and Shukui Qin. Their work appears in journals such as Nature, The Lancet and The Journal of Experimental Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.